NextCure, Inc. (NXTC) Form 8-K — Aug 6, 2026
NextCure reported a Q2 2026 net loss of $14.9 million, improved from $26.8 million a year earlier, with cash, cash equivalents, and marketable securities falling to $20.1 million from $41.8 million at year-end 2025. The quarter included $5.1 million of asset impairment charges tied to restructuring, and R&D expense dropped to $7.4 million from $24.1 million due to prior-year license fees not recurring. The results are framed by the pending all-stock merger with Avere Therapeutics announced July 14, 2026, alongside a concurrent private financing expected to generate approximately $320 million in gross proceeds immediately before closing.
Key figures
- Cash Position
- 20088000
- Cash dec 31 2025
- 41818000
- Ga expense q2 2025
- 3201000
- Ga expense q2 2026
- 2592000
- Rd expense q2 2025
- 24091000
- Rd expense q2 2026
- 7425000
- Cash decrease h1 2026
- $21.7 million
- Asset impairment q2 2026
- 5077000
- Atm equity sale proceeds
- $1.2 million
- Total assets dec 31 2025
- 50183000
- Total assets june 30 2026
- 22620000
- Weighted avg shares q2 2025
- 2374729
- Weighted avg shares q2 2026
- 5309724
- H1 2026 cash used in operations
- $23.1 million
- Stockholders equity june 30 2026
- 12149000
- Avere concurrent private financing gross proceeds
- approximately $320 million
Price after filing
Close on the filing date to close N calendar days later (from $5.78). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.